AllianceBernstein’s Protalix BioTherapeutics PLX Stock Holding History

AllianceBernstein’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$21.1K	Hold	11,720	–	–	﹤0.01%	3220
2025 Q4	$21.1K	Hold	11,720	–	–	﹤0.01%	3229
2025 Q3	$26K	Hold	11,720	–	–	﹤0.01%	3233
2025 Q2	$17.3K	Buy	+11,720	New	+$24K	﹤0.01%	3231
2024 Q2	–	Sell	-23,400	Closed	-$29.5K	–	3284
2024 Q1	$29.5K	Hold	23,400	–	–	﹤0.01%	3113
2023 Q4	$41.7K	Hold	23,400	–	–	﹤0.01%	3143
2023 Q3	$38.8K	Hold	23,400	–	–	﹤0.01%	3152
2023 Q2	$46.8K	Buy	+23,400	New	+$55.7K	﹤0.01%	3135
2014 Q2	–	Sell	-9	Closed	–	–	3590
2014 Q1	$0	Hold	9	–	–	﹤0.01%	3667
2013 Q4	$0	Hold	9	–	–	﹤0.01%	3472
2013 Q3	$0	Buy	+9	New	+$462	﹤0.01%	3492

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

AllianceBernstein's PLX Position: Q1 2026 in Review

AllianceBernstein held its Protalix BioTherapeutics (PLX) position steady in Q1 2026 at 11,720 shares worth $21.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3220.

AllianceBernstein first reported a position in PLX in Q3 2013 and has held it in 11 quarters since. The position peaked at $46.8K in Q2 2023. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

AllianceBernstein held 11,720 shares of Protalix BioTherapeutics worth $21.1K as of Q1 2026.
AllianceBernstein left its Protalix BioTherapeutics share count unchanged in Q1 2026.
Protalix BioTherapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #3220 holding.
AllianceBernstein first reported a position in Protalix BioTherapeutics in Q3 2013 and has held it in 11 quarters since.
AllianceBernstein's Protalix BioTherapeutics position peaked at $46.8K in Q2 2023.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.